Imperial College London
Alternate

Jiri Pavlu

Faculty of Medicine, Department of Immunology and Inflammation

Honorary Clinical Senior Lecturer
 
 
 
//

Contact

 

+44 (0)20 3313 8117j.pavlu Website

 
 
//

Location

 

Leuka Building R2.20Hammersmith HospitalHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Fernando:2021:10.2991/chi.k.211119.001,
author = {Fernando, F and Robertson, HF and El-Zahab, S and Pavl, J},
doi = {10.2991/chi.k.211119.001},
journal = {Clinical Hematology International},
pages = {130--141},
title = {How I use measurable residual disease in the clinical management of adult acute lymphoblastic Leukemia},
url = {http://dx.doi.org/10.2991/chi.k.211119.001},
volume = {3},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Over the last decade the use of measurable residual disease (MRD) diagnostics in adult acute lymphoblastic leukemia (ALL) has expanded from a limited number of study groups in Europe and the United States to a world-wide application. In this review, we summarize the advantages and drawbacks of the current available techniques used for MRD monitoring. Through the use of three representative case studies, we highlight the advances in the use of MRD in clinical decision-making in the management of ALL in adults. We acknowledge discrepancies in MRD monitoring and treatment between different countries, reflecting differing availability, accessibility and affordability.
AU  - Fernando,F
AU  - Robertson,HF
AU  - El-Zahab,S
AU  - Pavl,J
DO  - 10.2991/chi.k.211119.001
EP  - 141
PY  - 2021///
SN  - 2590-0048
SP  - 130
TI  - How I use measurable residual disease in the clinical management of adult acute lymphoblastic Leukemia
T2  - Clinical Hematology International
UR  - http://dx.doi.org/10.2991/chi.k.211119.001
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34938985
UR  - http://hdl.handle.net/10044/1/107274
VL  - 3
ER  -
Download